Leanne Cutler
GlaxoSmithKline (United Kingdom)(GB)
Publications by Year
Research Areas
Protein Degradation and Inhibitors, Multiple Myeloma Research and Treatments, Computational Drug Discovery Methods, Cholinesterase and Neurodegenerative Diseases, Alzheimer's disease research and treatments
Most-Cited Works
- → Discovery of Epigenetic Regulator I-BET762: Lead Optimization to Afford a Clinical Candidate Inhibitor of the BET Bromodomains(2013)302 cited
- → Orexin-A, an hypothalamic peptide with analgesic properties(2001)266 cited
- → Identification of a novel series of BET family bromodomain inhibitors: Binding mode and profile of I-BET151 (GSK1210151A)(2012)207 cited
- → Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762(2013)202 cited
- → Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo(2006)198 cited
- → The Discovery of I-BET726 (GSK1324726A), a Potent Tetrahydroquinoline ApoA1 Up-Regulator and Selective BET Bromodomain Inhibitor(2014)187 cited
- → Improving the in Vitro Prediction of in Vivo Central Nervous System Penetration: Integrating Permeability, P-glycoprotein Efflux, and Free Fractions in Blood and Brain(2006)176 cited
- → Second Generation of Hydroxyethylamine BACE-1 Inhibitors: Optimizing Potency and Oral Bioavailability(2008)65 cited
- → Pharmacokinetics of the novel, high-affinity and selective dopamine D3 receptor antagonist SB-277011 in rat, dog and monkey:in vitro/in vivocorrelation and the role of aldehyde oxidase(2001)63 cited
- → Second generation of BACE-1 inhibitors part 3: Towards non hydroxyethylamine transition state mimetics(2009)54 cited